BIOMAT Database Logo BIOMAT Database Logo

[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. 2017

Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Assistance publique-Hôpitaux de Paris, hôpital Cochin, service d'oncologie médicale, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: sixtine.depercin@gmail.com.

UI MeSH Term Description Entries
D007107 Immune System The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components. Immune Systems,System, Immune,Systems, Immune
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010601 Pharmacology, Clinical The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans. Clinical Pharmacology
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069196 Gastrointestinal Microbiome All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. Enteric Bacteria,Gastric Microbiome,Gastrointestinal Flora,Gastrointestinal Microbial Community,Gastrointestinal Microbiota,Gastrointestinal Microflora,Gut Flora,Gut Microbiome,Gut Microbiota,Gut Microflora,Intestinal Flora,Intestinal Microbiome,Intestinal Microbiota,Intestinal Microflora,Bacteria, Enteric,Flora, Gastrointestinal,Flora, Gut,Flora, Intestinal,Gastric Microbiomes,Gastrointestinal Microbial Communities,Gastrointestinal Microbiomes,Gastrointestinal Microbiotas,Gut Microbiomes,Gut Microbiotas,Intestinal Microbiomes,Intestinal Microbiotas,Microbial Community, Gastrointestinal,Microbiome, Gastric,Microbiome, Gastrointestinal,Microbiome, Gut,Microbiome, Intestinal,Microbiota, Gastrointestinal,Microbiota, Gut,Microbiota, Intestinal,Microflora, Gastrointestinal,Microflora, Gut,Microflora, Intestinal
D000077594 Nivolumab A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. BMS-936558,MDX-1106,ONO-4538,Opdivo,BMS 936558,BMS936558,MDX 1106,MDX1106,ONO 4538,ONO4538
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].
September 2017, Bulletin du cancer,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
November 2018, Bulletin du cancer,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Clinical pharmacology of anticancer drugs.
June 1977, Seminars in oncology,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
December 2018, Bulletin du cancer,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
[Clinical pharmacology and toxicology of anticancer drugs].
February 2015, Nihon rinsho. Japanese journal of clinical medicine,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Pharmacology of anticancer drugs.
March 1977, National Cancer Institute monograph,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Pharmacology of anticancer drugs.
December 1984, Cancer treatment reviews,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
[On the pharmacology of anticancer drugs].
January 1967, Revista clinica. Lisbon. Instituto Maternal,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.
June 2021, Cytokine & growth factor reviews,
Sixtine de Percin, and Marine Fidelle, and Edith Carton, and François Goldwasser
Combinations of anticancer drugs and immunotherapy.
November 2003, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!